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        Alzheimer  ’  s disease (AD) is characterized by 
abnormal senile plaque and neurofi  brillary tan-
gle formation. Derived from the amyloid-     (A    ) 
precursor protein (A    PP), A     peptide is the ma-
jor component of senile plaques in the brain and 
cerebrovasculature. A     is thought to be a major 
contributor to the neurodegenerative process, 
acting either through neurotoxic mechanisms 
or local infl  ammatory processes (  1  ). However, 
Alzheimer  ’  s pathology is not limited to neurons, 
as one of the earlier manifestations of the disease 
is abnormal cerebral vasculature. This neuro-
vascular pathology may accelerate other A    -
mediated pathologies or aff  ect neuronal damage 
directly (  2  –  4  ). 
  Fibrinogen is a 340-kD macromolecule 
classically known for its role as the protein com-
ponent of blood clots and is normally excluded 
from the brain parenchyma by the blood  –  brain 
barrier. Neurovascular damage can allow fi  -
brinogen access to the central nervous system. 
Fibrinogen is present in the brains of AD pa-
tients (  5  ), but the pathologic signifi  cance is 
not known. 
  Fibrin deposition increases in the context of 
defi  ciency in the tissue plasminogen activator/
plasminogen (tPA/plg) protease cascade (  6  ). 
Plasminogen-defi  cient mice accumulate extra-
vascular fi  brin and have impaired wound healing 
and high mortality, both of which are corrected 
in mice defi  cient for both plasminogen and 
fi  brinogen (  7  ). Fibrin accumulation can also be 
reduced genetically or pharmacologically with 
administration of the fi  brinogen-depleting pro-
tease ancrod. This serine protease derived from 
the venom of the Malayan pit viper   Agkistrodon 
rhodostoma   has been used to alleviate fi  brin-
  mediated pathology in various systems (  8, 9  ). 
  In the brains of AD patients and mouse 
models of the disease, clearance of fi  brin by the 
tPA/plasmin system is expected to be reduced as 
tPA activity is diminished ( 10, 11 ). Because infl  am-
mation is universal in A    PP transgenic mice and 
can be observed as early as 13 wk of age (  12  ), 
we hypothesized that extravasated fi  brin might 
initiate or exacerbate the observed neuroin-
fl  ammation. We further hypothesized that this 
exaggerated fi  brin-induced infl  ammatory process 
could infl  ate the damage to the vasculature, thus 
promoting this process of disease progression. 
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  Cerebrovascular dysfunction contributes to the pathology and progression of Alzheimer  ’  s 
disease (AD), but the mechanisms are not completely understood. Using transgenic mouse 
models of AD (TgCRND8, PDAPP, and Tg2576), we evaluated blood  –  brain barrier damage and 
the role of fi  brin and fi  brinolysis in the progression of amyloid-     pathology. These mouse 
models showed age-dependent fi  brin deposition coincident with areas of blood  –  brain barrier 
permeability as demonstrated by Evans blue extravasation. Three lines of evidence suggest 
that fi  brin contributes to the pathology. First, AD mice with only one functional plasminogen 
gene, and therefore with reduced fi  brinolysis, have increased neurovascular damage relative 
to AD mice. Conversely, AD mice with only one functional fi  brinogen gene have decreased 
blood  –  brain barrier damage. Second, treatment of AD mice with the plasmin inhibitor tranex-
amic acid aggravated pathology, whereas removal of fi  brinogen from the circulation of AD mice 
with ancrod treatment attenuated measures of neuroinfl  ammation and vascular pathology. 
Third, pretreatment with ancrod reduced the increased pathology from plasmin inhibition. 
These results suggest that fi  brin is a mediator of infl  ammation and may impede the reparative 
process for neurovascular damage in AD. Fibrin and the mechanisms involved in its accumula-
tion and clearance may present novel therapeutic targets in slowing the progression of AD. 2000 FIBRIN-MEDIATED INFLAMMATION IN AD MICE | Paul et al.
Because Evans blue dye binds to albumin in the blood, extrav-
asation of the dye serves as a marker for blood  –  brain barrier 
permeability and neurovascular damage. We compared Al-
zheimer  ’  s mouse models Tg2576, PDAPP, and TgCRND8 to 
nontransgenic littermates for defects in the neurovasculature. 
Because these mice bear A    PP with diff  erent familial AD mu-
tations and are driven by diff  erent promoters, they exhibit 
diff  ering ages of onset of A    -associated pathology. Therefore, 
we compared extravasation of Evans blue dye in mice at 6 and 
12 mo of age. 
  As shown in   Fig. 1 A  , brains of all three Alzheimer  ’  s 
mouse models were considerably more permeable to the 
dye.   Nontransgenic littermates showed increased blood  –
  brain barrier permeability as age increased. However, in all 
three Alzheimer  ’  s mouse models, the brain was considerably 
more permeable to the dye at these ages. These data are con-
sistent with previously observed microvascular damage in the 
  We sought to examine these possibilities by measuring 
blood  –  brain barrier permeability and fi  brin deposition in three 
mouse models of AD. Our results demonstrate blood  –  brain bar-
rier damage and the presence of fi  brin in the parenchyma in AD 
mice. Modulation of fi  brinogen levels aff  ects the pathology of 
AD mice: reducing fi  brinolysis, thereby increasing fi  brin deposi-
tion, worsens the pathology, whereas fi  brinogen depletion at-
tenuates microgliosis and neurovascular damage. These results 
indicate a role for fi  brin in aggravating and accelerating the 
infl  ammatory component of disease progression in transgenic 
A    PP-overexpressing mice. 
    RESULTS   
  Fibrin is deposited through a disrupted neurovasculature 
in transgenic mouse models of AD 
  When the blood  –  brain barrier is compromised, macromolecules 
in circulation can accumulate in the brain parenchyma (  13  ). 
  Figure 1.     Blood  –  brain barrier permeability and neurovascular damage is increased in three mouse models of AD. (A) Evans blue assay indicates 
increased blood  –  brain barrier permeability in the Tg2576, PDAPP, and TgCRND8 transgenic mice compared with nontransgenic (NTg) littermates. Data are 
given as Evans blue extravasation calculated from A  620   of perfused brain homogenates and normalized to plasma Evans blue levels. For 6-mo mice,   n    9 
for NTg (three each from Tg2576, PDAPP, and TgCRND8 litters),   n    3 for Tg2576,   n    6 for PDAPP, and   n    7 for TgCRND8; for 12-mo mice,   n    9 for 
NTg (three each from Tg2576, PDAPP, and TgCRND8 litters),   n    4 for Tg2576,   n    4 for PDAPP, and   n    4 for TgCRND8. Error bars represent the mean  
SEM. *, P  0.05; **, P  0.001, relative to nontransgenic littermates. (B) Laser-scanning micrograph of microvasculature in hippocampus of 6-mo 
TgCRND8 mouse and NTg littermate injected with Evans blue (red) 6 h before and perfused at the time of killing with 2,000-kD dextran (green). Fluores-
cence intensity across a cross section (indicated by white arrow; 100     m) of a capillary is scanned for the distribution of each fl   uorochrome.   JEM VOL. 204, August 6, 2007 
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circulation by ancrod. Accordingly, sections of perfused brains 
after ancrod treatment showed diminished fi  brin immuno-
reactivity (see   Fig. 7 A  ). 
  Perfused sections of transgenic brains from each treatment 
group were stained with CD11b, an integrin receptor present 
on microglia, and infl  ammatory foci were visualized. The total 
area of infl  ammatory foci can be quantifi  ed within the regions 
of interest, as shown in   Fig. 3 A  .   Areas of infl  ammation were 
compared between ancrod and saline. Ancrod treatment re-
duced the area of infl  ammation by     64% (  Fig. 3 C  ; P = 
0.00001). In saline-treated mice, microglia were identifi  ed by 
their amoeboid morphology. As shown in   Fig. 3 D  , these ag-
gregated microglia formed infl  ammatory foci and appeared to 
concentrate around plaques with reduced number after fi  -
brinogen depletion. Because ancrod is a protease and could 
be acting directly on A     levels, we quantifi  ed levels of plasma 
A      1-40   and cortical A    , neither of which were substantially 
diff  erent in ancrod-treated mice (  Fig. 3 B  ), indicating that 
depletion of fi  brinogen, rather than deposited A    , is respon-
sible for the reduced microgliosis. 
  As infl  ammation can contribute to blood  –  brain barrier 
permeability, we assayed ancrod-treated mice for Evans blue 
extravasation and found a reduction when compared with 
saline-treated mice (see   Fig. 7 B  ). This attenuation of vascular 
damage prompted analysis of the microvasculature from both 
cortex and hippocampus. Identical areas of the brain (  Fig. 
4 A  ) were quantifi  ed for vascular density as a percentage of 
image area (  Fig. 4 B  ) and indicated that ancrod treatment 
partially prevents blood vessel loss.   
Tg2576 mouse (  14  ), although the TgCRND8 mice show 
earlier onset. 
  To visually observe extravascular deposition of Evans 
blue, mice treated with Evans blue for 6 h were perfused 
with fl  uorescent dextran at the time of killing. This 2,000-kD 
dextran is impermeable to both healthy and damaged blood 
vessels, and therefore serves as an outline of intravascular 
space. The nontransgenic littermate blood  –  brain barrier re-
tained both dyes within the blood vessel as shown in   Fig. 1 B 
(left)  . The damaged TgCRND8 blood vessel in   Fig. 1 B 
(right)   showed diff  use accumulation of Evans blue around the 
contained dextran. As shown underneath each micrograph, 
the distribution of each fl  uorochrome can be analyzed for 
fl   uorescence intensity across a cross section of a capillary, 
which reveals Evans blue with a broader distribution than 
the dextran in the AD mouse (  15  ). Together with the quan-
titative extravasation assay, these comprehensive estimates in-
dicated increased blood  –  brain barrier permeability in the 
TgCRND8 mouse. 
  To gain insight into blood vessel health, mice brain 
sections were stained for platelet/endothelial cell adhesion 
molecule-1 (PECAM-1). Images of perfused and stained 
microvasculature were obtained from the cortex of TgCRND8 
mice and nontransgenic littermates at 6 mo of age (Fig. S1, avail-
able at http://www.jem.org/cgi/content/full/jem.20070304/
DC1). Healthy endothelial cells constitutively express this 
surface marker (  16  ), but sections of TgCRND8 brains showed 
diminished signal intensity, and vessels appeared tortuous 
and fragmented. 
  Because the AD mouse blood  –  brain barrier was perme-
able to albumin-bound Evans blue dye, we hypothesized that 
fi  brinogen could gain access to the brain  ’  s extravascular space. 
Given this, and because tPA activity is reduced in the AD 
mouse brain (  11  ), we reasoned that fi  brin could deposit 
and accumulate over the lifespan of the mouse. Perfused 
TgCRND8 brains contained elevated levels of fi  brin as deter-
mined by ELISA. 3  –  9-mo-old mice showed that A     accumu-
lated in an age-dependent manner, and fi  brin levels correlated 
with soluble A      1-40   and A      1-42   levels, as measured by ELISA 
from the same tissue homogenates (  Fig. 2  ).   
  Neuroinfl  ammation and microvascular injury are diminished 
by pharmacologic depletion of fi  brinogen 
  Because fi  brin is a proinfl  ammatory molecule and could ag-
gravate pathology upon exiting the vasculature (  17, 18  ), we 
asked if fi  brinogen depletion might reduce the infl  ammation 
in A    PP transgenic mice. TgCRND8 mice are appropriate 
because of the early onset of neurovascular dysfunction and 
neuroinfl  ammation, as seen by microgliosis at 13 wk (  12  ). We 
therefore reduced circulating fi  brinogen levels using a recom-
binant form of the Malayan pit viper protease ancrod. Ancrod 
is a thrombin-like protease that cleaves fi  brin and prevents 
its polymerization, allowing degradation by the liver and 
removal from circulation (  19, 20  ). TgCRND8 mice were 
treated with either ancrod or saline for 4 wk before killing at 
6 mo of age. Fibrinogen levels were reduced by 50  –  75% in 
  Figure 2.     Fibrinogen accumulates through the damaged neurovas-
culature. (A) Fibrin deposition parallels age-dependent A     accumulation. 
TgCRND8 cortex and hippocampus were isolated, and homogenates were 
assayed each for fi  brinogen and A    1-40   by ELISA. Each point represents 
one TgCRND8 mouse. Correlation coeffi  cients are indicated. (B) The same 
cortex and hippocampus homogenates were assayed each for fi  brinogen 
and A    1-42   by  ELISA.   2002 FIBRIN-MEDIATED INFLAMMATION IN AD MICE | Paul et al.
  Neurovascular pathology in the transgenic mouse model 
is modulated by genetic defi  ciency in plasminogen 
or fi  brinogen 
  We crossed transgenic AD mice to mice defi  cient for fi  brino-
gen (fi  b/) to obtain TgCRND8;fi  b+/ mice bearing only 
one copy of the fi  brinogen gene. Additionally, because accu-
mulated fi  brin in the extravascular space can cause damage, we 
asked if a reduction in plasminogen levels on a background of 
the A    PP transgene could promote neurovascular pathology. 
Similar to the fi  brinogen cross, we generated TgCRND8;plg+/ 
mice and compared them to TgCRND8 littermates. We ex-
amined the N1 generation from mice crossed to TgCRND8 
mice because pathology presents at an earlier age than PDAPP 
and Tg2576. Heterozygosity for plasminogen defi  ciency in 
TgCRND8 mice produced a signifi  cant increase in Evans blue 
extravasation ( Fig. 5;  P = 0.042).  Conversely, TgCRND8;fi  b+/ 
mice showed reduced neurovascular pathology at 6 mo (P  
0.003). Plg+/ and fi  b+/ controls showed little permeability 
to the dye, suggesting that a product of the A    PP transgene is 
necessary for neurovascular pathology. To control for the 
possible eff  ects of diff  erent genetic backgrounds on the produc-
tion and metabolism of the A    PP transgene, PDAPP mice 
were backcrossed 10 generations onto the C57BL/6 back-
ground before crossing with plg/ mice, which share the C57 
background. The results shown in Fig. S2 (available at http://
www.jem.org/cgi/content/full/jem.20070304/DC1) indicate 
  Neurovascular pathology is promoted by pharmacologic 
inhibition of fi  brinolysis 
  To complement fi  brinogen-depletion experiments, we tested 
whether absence of plasmin-mediated clearance of fi  brin accel-
erates pathology. We treated TgCRND8 mice with a plasmin 
inhibitor, tranexamic acid, for 4 wk before killing at 6 mo of 
age alongside littermates treated with saline or ancrod. Infl  am-
matory foci were again visualized using microglia staining with 
CD11b (  Fig. 3 A  ). Plasmin inhibition by tranexamic acid treat-
ment signifi   cantly increased microgliosis in treated mice as 
compared with control mice (P  0.014;   Fig. 3 C  ). 
  We also reasoned that the inhibition of plasmin-mediated 
clearance of fi  brin and subsequent infl  ammation could aggra-
vate neurovascular damage in TgCRND8 mice. We observed 
that administration of tranexamic acid increases damage to the 
blood  –  brain barrier (see   Fig. 7  ). Decreased blood  –  brain bar-
rier integrity after 4-wk tranexamic acid treatment prompted 
analysis of the microvasculature. Tranexamic acid  –  treated 
TgCRND8 mice showed a reduction in microvascular den-
sity, and vessels appeared damaged (  Fig. 4  ). 
  With the increased pathology observed in the tranexamic 
acid  –  treated animals, we asked if infl  ammation and A     were 
suffi   cient to promote neurodegeneration. Active caspase-3 
staining did not reveal apoptotic cells in treatment or control 
groups. Samples also were negative for neurodegeneration by 
Fluoro-Jade B staining (unpublished data). 
  Figure 3.     Fibrinogen depletion and inhibition of fi  brinolysis in the 6-mo TgCRND8 mouse have opposite effects on neuroinfl  ammation. 
(A) Representative immunofl  uorescent images of brains colabeled for A     (left) and CD11b, a marker for activated microglia (right). Regions of interest 
are outlined to demark the cortical region quantifi  ed in each image. Images show increased density of infl  ammatory foci in the cortex of plasmin-
inhibited transgenic mice, whereas fi  brinogen-depleted transgenics show decreased density relative to age-matched saline-treated TgCRND8 mice. Bar, 
200     m. (B) Analysis of total A     staining within marked regions of interest in the cortex; the differences were not signifi  cant (P  0.05). (C) Analysis of 
CD11b staining shows increased infl  ammation density in the cortex of plasmin-inhibited transgenic mice, whereas fi  brinogen-depleted transgenics show 
a decrease. Error bars present the mean  SEM of four images for each of fi  ve ancrod-, four tranex-, and two saline-treated mice. *, P  0.05; **, P  0.001, 
relative to saline-treated mice. (D) High-magnifi  cation images of microglia (green) and A     plaques (red) in each treatment group. Bar, 50    m.   JEM VOL. 204, August 6, 2007 
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  Fibrinogen depletion protects against the deleterious effects 
of plasmin inhibition 
  Suppressing plasmin activity with tranexamic acid leads to 
increased blood  –  brain barrier breakdown and infl  ammation, as 
shown in   Fig. 7 B   and   Fig. 3 C  , respectively.   As fi  brin is the 
primary target of plasmin proteolysis, this treatment also led to 
increased fi  brin deposition (  Fig. 7 A  ). However, because plas-
min is a potent protease that could have many substrates, we 
investigated whether the vascular damage and infl  ammation 
were due to fi  brin accumulation or some other eff  ect of plas-
min inhibition. Therefore, we implanted pumps with either 
saline or ancrod in two groups of mice for a pretreatment pe-
riod of 1 wk. After pretreatment, both fi  brinogen-depleted 
and control groups received tranexamic acid, to inhibit plas-
min activity for 1 wk. All mice were assayed for blood  –  brain 
barrier damage and infl  ammation as before. As expected, plas-
min inhibition increased Evans blue extravasation and mi-
croglial staining in the control group. By comparison, the 
fi  brinogen-depleted group showed considerably less pathology 
(  Fig. 8  ).   Levels for fi  brinogen-depleted mice were similar to 
those of untreated mice (  Fig. 1 A  ), suggesting that fi  brinogen 
depletion protected mice from the increased vascular damage 
and infl  ammation induced by plasmin inhibition. This result 
indicates that fi  brin deposition is a critical pathologic conse-
quence of reduced plasmin activity in the brains of AD mice. 
    DISCUSSION   
  Neurovascular dysfunction in the A    PP transgenic mouse 
  The Tg2576 mouse has defi  cits in vascular integrity shown by 
blood  –  brain barrier damage (  21, 22  ), decreased blood fl  ow, and 
increased susceptibility to ischemia (  23  ). In addition, vascular den-
sity is reduced in these animals, as measured by glucose transporter 
increased blood  –  brain barrier pathology in PDAPP;plg+/ 
mice when compared with PDAPP littermates, consistent with 
the results shown in   Fig. 5  . 
  Because Evans blue dye is fl  uorescent, the entire hemisphere 
can be visualized for dye extravasation to determine which areas 
of the brain are most aff  ected. Images of cerebral hemispheres of 
each genotype were compared (  Fig. 6  ).   The cortex and hippo-
campus were aff  ected with the highest levels of neurovascular 
damage, consistent with the observation that hippocampus and 
cortex show the most A     deposition. The data indicated that the 
removal of one copy of the plasminogen gene accelerates the loss 
of microvascular integrity in TgCRND8 mice, whereas reduc-
tion of one copy of the fi  brinogen gene slowed pathogenesis. 
At 3 mo of age, mice homozygous for plasminogen defi  ciency 
showed blood  –  brain barrier damage (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20070304/DC1) but did 
not show substantial neuroinfl  ammation. Because these mice 
died early, it cannot be determined if the infl  ammation would 
have developed to levels comparable to those of older AD mice. 
Nonetheless, this fi  nding indicates that the presence of A     ex-
aggerates fi  brin-related neuroinfl  ammation. 
  Figure 4.     Fibrinogen depletion and inhibition of fi  brinolysis in the 
TgCRND8 mouse have opposite effects on neurovascular damage. 
(A) Neurovasculature in ancrod-, saline-, and tranexamic acid  –  treated 
TgCRND8 mice. Images of brains labeled for PECAM-1 (black) are shown 
with higher magnifi  cation images of the regions shown in red to the 
right. Regions defi  ning cortex (orange) and hippocampus (blue) were used 
for quantifi  cation of vascular density. The images show decreased vascu-
lar density in the cortex (cx) and hippocampus (hp) of plasmin-inhibited 
transgenic mice, whereas fi  brinogen-depleted transgenics show increased 
vascular density over age-matched saline-treated TgCRND8 mice at 6 mo. 
(B) Semiquantitative analysis of PECAM-1 staining in the cortex and hippo-
campus shows decreased vascular density in plasmin-inhibited transgenic 
mice, whereas fi  brinogen-depleted transgenics show an increase. Bars 
represent the percentage of image area reported as the mean  SEM of 
four images of the cortex and hippocampus of four mice in each treat-
ment group. *, P  0.05; **, P  0.001, relative to saline-treated mice.     
  Figure 5.     Genetic plasminogen and fi  brinogen defi  ciency modulate 
defects in the AD mouse blood  –  brain barrier. 6-mo-old AD mice defi  -
cient for plasminogen (TgCRND8;plg+/) and fi  brinogen (TgCRND8;fi  b+/) 
were assayed for Evans blue extravasation alongside TgCRND8 littermates. 
TgCRND8;plg+/ mice showed increased blood  –  brain barrier permeability, 
whereas TgCRND8;fi  b+/ mice showed a decrease. Data are given as 
Evans blue extravasation calculated from A  620   of perfused brain homogenates 
and normalized to plasma Evans blue levels.   n    8 for NTg;   n    8 for 
TgCRND8; and   n    3 for TgCRND8;plg+/, TgCRND8;fi  b+/, fi  b+/, and plg+/ 
mice. Bars represent the mean  SEM. **, P  0.001, relative to nontrans-
genics;    †  ,  P   0.05, relative to TgCRND8.     2004 FIBRIN-MEDIATED INFLAMMATION IN AD MICE | Paul et al.
  The A     peptide causes endothelial and smooth muscle 
cell dysfunction and cell death in vitro, thus disrupting two 
major components of the blood  –  brain barrier (  25  –  31  ). There-
fore, the initial insult to the microvasculature likely arises from 
increased A     levels. Cerebral amyloid angiopathy is a hall-
mark of AD, and it will be important to consider the specifi  c 
vascular amyloid burden in these mice. 
type 1 beginning at 12 mo (  24  ). Subsequently, it was shown 
that the blood  –  brain barrier compromise is rescued in the 
Tg2576 mouse with passive A      1-40   peptide immunization (  14  ). 
The present study explores the contribution of fi  brin to neuro-
vascular damage as part of the A     disease process and broadens 
the knowledge of vascular defi  cits to other A    PP-transgenic 
mouse models. 
  Figure 6.     Localization of vascular pathology in AD mice defi  cient for fi  brinogen or fi  brinolysis. (A  –  F) Composite images of cerebral hemispheres 
of 6-mo-old mice perfused with Evans blue for 6 h. TgCRND8;fi  b+/ (D) and TgCRND8;plg+/ (F) mice are compared with TgCRND8 mice (E) and fi  b+/ (A), 
NTg (B), and plg+/ (C) controls. Pathologic dye accumulation is most apparent in the cortex (cx), hippocampus (hp), and thalamus (th).     
  Figure 7.     Fibrin deposition and vascular damage are modifi  ed by manipulation of fi  brinogen levels and fi  brinolysis. (A) Representative images 
of perfused brains from each treatment group stained for fi  brin. Images were tiled together using a motorized stage on a confocal microscope. (B) Evans 
blue extravasation from ancrod-, saline-, and tranexamic acid  –  treated 6-mo TgCRND8 mice. Data are represented as mean  SEM of each treatment 
group, where   n    3 for each group. *, P  0.05, relative to saline-treated mice. Fibrinogen depletion with ancrod reduces vascular damage, whereas 
plasmin inhibition enhances permeability. (C) High-magnifi  cation images of fi  brin deposition (green) with A     plaques (red). Bar, 20    m.   JEM VOL. 204, August 6, 2007 
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Additionally, plg/ mice exhibit early mortality, which would 
preclude comparison at later ages. TgCRND8;fi  b/ mice 
are also diffi   cult to generate because of breeding restrictions 
and limited survival (  36  ). 
  These genetic constraints are addressed with the experi-
ments using pharmacologic reduction of fi  brinolysis and fi  -
brinogen depletion by ancrod. The convergence of the results 
of both genetic and pharmacologic approaches forms solid evi-
dence that manipulation of fi  brin levels in Alzheimer  ’  s mouse 
models modulates infl  ammation and vascular integrity. 
  Fibrinogen and infl  ammation 
  Fibrinogen has several active roles in normal and abnor-
mal physiology, including cellular responses in clotting and 
infl  ammation that are mediated by fi  brinogen receptors. Of 
interest in the present study are the integrin receptors ex-
pressed on leukocytes, monocytes, and macrophage/microglia. 
Three notable infl  ammatory integrins are   	    5        1  ,   	    v        3  , and 
  	    M        2   (Mac-1 or CD11b/CD18; reference   37  ). Binding of the 
fi  brinogen dimer to microglial   	    M        2  /CD11b elicits activa-
tion of the NF-  
  B pathway, causing increased expression of 
cytokine genes (  38, 39  ). 
  The involvement of infl  ammation has been studied in 
AD. Clinical and epidemiological data concerning anti-
infl  ammatory medications are provocative and require fur-
ther studies to determine their potential in controlling disease 
progression (  40, 41  ). The present study suggests that fi  brin 
may be an upstream eff  ector of neuroinfl  ammation, and the 
damaging eff  ect of decreased fi  brinolysis on the neurovas-
culature is intriguing. Fibrin-induced microgliosis could be 
toxic to endothelial cells, as microglia have been shown to 
increase cell death in primary endothelial cells after oxygen-
glucose deprivation, which can be reduced by inhibiting 
microglial activation with minocycline (  42  ). 
  How infl  ammation may contribute to neurodegeneration 
in AD is still largely unknown. As blood vessels from AD 
brains are directly toxic to neurons (  43  ), we asked if the com-
promised neurovasculature and infl  ammation in these experi-
mental mice could promote neurodegeneration. Although 
we did not observe neuronal death, studies involving older 
TgCRND8 mice with enhanced infl  ammation and vascular 
damage may reveal detectable levels of neurodegeneration. 
  As fi  brinogen is polymerized after activation by throm-
bin, it is important to note that thrombin injection into the 
rat cortex induces microgliosis (  44  ). Additionally, in human 
patients with advanced AD, plasma prothrombin can be found 
in the extravascular space (  45  ), which provides an environ-
ment where fi  brin is likely to deposit. 
  Once polymerized in the parenchyma, fi  brin is covalently 
cross-linked by tissue-resident transglutaminase factor XIII (  46  ). 
Cross-linked fi  brin is stabilized by covalent bonds between 
     chains. Because the capturing antibody used in the ELISA 
recognizes the      chain specifi  cally (  47  ), some insoluble fi  -
brin may have escaped detection, and the ELISA results 
likely underestimate the total fi  brin deposition. However, the 
immunofl  uorescence uses a polyclonal antibody, which detects 
  However, the neurovascular damage in the plasminogen-
defi   cient mouse suggests that decreased fi  brinolysis  might 
promote the damage to blood vessels and subsequent fi  brin 
deposition. The necessity of A     to initiate the infl  ammatory 
process is indicated by the low level of neuroinfl  ammation in 
the plasminogen-defi  cient mouse. 
  AD and the tPA/plasmin fi  brinolytic system 
  tPA/plasmin fi  brinolytic activity is regulated by serine prote-
ase inhibitors (serpins), such as plasminogen activator inhibi-
tor-1 (PAI-1). In mice, PAI-1 is up-regulated in the presence 
of A    , which agrees with the clinically observed elevation of 
PAI-1 levels in the cerebrospinal fl  uid of AD patients (  11, 27, 
32  ) and decreased plasmin activity in the AD brain (  10  ). 
  The tPA/plasmin system is down-regulated in AD, in 
accord with reductions in other naturally occurring A    -
degrading proteases (  10, 33, 34  ). The direct consequences of 
this general lack of protease activity might be the diminished 
clearance of A     peptide (  34  ). The present study proposes that 
decreases in clearance of fi  brin can also contribute to the pro-
gression of A     pathology. 
  It is important to consider the eff  ects of the loss of a single 
copy of the plasminogen gene. Heterozygosity decreases the 
fi  brinolytic activity to 55% of normal in pooled plasma ob-
tained from wild-type mice according to clot lysis assays (  35  ). 
We did not attempt to generate TgCRND8;plg/ mice be-
cause plg/ mice develop several thrombotic complications, 
which could complicate the central nervous system pathology. 
  Figure 8.     Ancrod treatment protects AD mice from increased 
pathology induced by tranexamic acid. (A) Two groups of 6-mo TgCRND8 
mice were treated as indicated. (B) Evans blue extravasation. (C) Analysis 
of CD11b staining. In both cases, pretreatment with ancrod reduced the 
effect of tranexamic acid. Error bars present the mean  SEM of four 
images for each of four ancrod- and four saline-treated mice. **, P  0.001.    2006 FIBRIN-MEDIATED INFLAMMATION IN AD MICE | Paul et al.
Carl Zeiss MicroImaging, Inc.). Optical slices were processed by AxioVision 
confocal imaging software, and reconstructed images were evaluated for 
Evans blue dye present outside the fl  uorescein-delineated intraluminal space. 
For views of the entire brain hemisphere, a composite of stitched 10 images 
(8  8) was produced during acquisition with a motorized stage. 
  ELISA (brain or plasma).     Brains were perfused, weighed, and homoge-
nized in 0.1 M Tris, pH 7.2/0.2% Triton X-100 with 5 mM EDTA, 100 mM 
tranexamic acid, and protease inhibitor cocktail (Roche). Protein concentrations 
were measured by Lowry Assay (Bio-Rad Laboratories, Inc.). Quantifi  cation 
of fi  brinogen was performed using a hamster anti  –  mouse fi  brinogen-capturing 
antibody, 7E9, provided by M. Jirouskova (The Rockefeller University, New 
York, NY; reference   47  ) and HRP-conjugated rabbit anti  –  human fi  brinogen-
detecting antibody (DakoCytomation). A     levels were measured by ELISA 
according to the manufacturer  ’  s protocol (Biosource International). 
  Immunostaining and semiquantitative analysis.     To localize the leak-
age of Evans blue dye, one brain hemisphere was sectioned and fi  xed with 
ice-cold ethanol. To evaluate fi  brinogen extravasation and deposition, sec-
tions from Evans blue dye  –  treated animals were processed for fi  brinogen 
immunoreactivity with a FITC-conjugated anti-fi  brinogen antibody (Dako-
Cytomation). Microglial staining was performed with a biotin-conjugated 
anti-CD11b antibody (1:100; BD Biosciences) visualized with FITC- or 
Rhodamine-conjugated avidin (1:500). To analyze microvasculature, rat 
anti  –  PECAM-1 antibody (BD Biosciences) was used (1:50) and visualized 
with an FITC-conjugated goat anti  –  rat antibody (1:1,000). A     was detected 
with a rabbit anti  –  pan-A     antibody (1:100; Biosource International). Apop-
totic cells were stained with a rabbit anti  –  active caspase-3 antibody (1:200; 
Cell Signaling Technology, Inc.). 
  Coronal sections (from bregma   −  1.5 to   −  2.0 mm) were processed and 
stained for the markers listed above. A composite (3  3) of 10 images was 
stitched together to include hippocampus and cortex during acquisition us-
ing a laser-scanning confocal imaging system equipped with a motorized 
stage (LSM 510 confocal system fi  tted on an Axiovert 200 inverted micro-
scope). Composite images were converted 1-bit images using ImageJ (http://
rsb.info.nih.gov/ij/). Using this bit depth, regions including hippocampus, 
cortex, or both were selected by hand as shown in   Figs. 3 and 4   and quanti-
fi  ed for percentage of immunofl  uorescence. 
  Fluoro-Jade B staining.     Fluoro-Jade B staining was performed according 
to the protocol by Schmued and Hopkins (  54  ) and viewed under fl  uores-
cence microscopy. In brief, sections were immersed sequentially in 1% 
NaOH/80% alcohol for 2 min, 70% alcohol for 2 min, water for 2 min, 
0.06% potassium permanganate for 10 min, water for 2 min, and 0.0004% 
Fluoro-Jade B in 1% acetic acid for 20 min, and then rinsed in water three 
times. The sections were then dried, immersed in Histoclear, and mounted 
with neutral DPX polystyrene medium. The sections were viewed under 
blue-green excitation light with a fl  uorescent microscope. 
  Ancrod/tranexamic acid treatments.     To explore whether removal of 
fi  brinogen from the circulation can aff  ect the progression of A     pathology, we 
treated transgenic mice with Viprinex (ancrod; provided by D.E. Levy, Neuro-
biological Technologies, Inc., Emeryville, CA). Mini-osmotic pumps were 
subcutaneously implanted to deliver 4 U/day of ancrod activity over 4 wk 
with replacement at 2 wk while a control group received saline (DURECT 
Corp.). To measure the fi  brinogen-depletion eff  ect of ancrod, plasma samples 
were obtained weekly by tail prick, and fi  brinogen was quantifi  ed by ELISA. 
  Defi  ciency in fi  brinolysis was accomplished pharmacologically by im-
plantation of a mini-osmotic pump for delivery of tranexamic acid. Because 
the drug is also orally active, this dosage was supplemented with tranexamic 
acid dissolved in drinking water at 20 mg/ml. The total daily dose was esti-
mated to be 100 mg/day. 
  Online supplemental material.     Fig. S1 shows examples of neurovascular 
staining in untreated 6-mo NTg and TgCRND8 mice. Fig. S2 shows 
PDAPP;plg+/ mice compared with PDAPP littermates, and references the 
all forms of fi  brinogen. Similarly, Triton X-100  –  soluble A     
levels likely underestimate the total A     burden. However, 
A     levels measured by ELISA correlate with plaque burdens 
observed with immunofl  uorescence. Both soluble and insol-
uble fi  brin activates microglia via the CD11b receptor and 
contributes to the observed infl  ammation in A    PP transgenic 
mice and AD patients. 
  This study begins to outline a role for fi  brin in the neuro-
infl  ammation seen in AD. These results also indicate a role 
for fi  brin deposition in accelerating the neurovascular dam-
age observed in these mouse models and perhaps in reduc-
ing the brain  ’  s reparative capacity. Extravascular fi  brinogen 
functioning as a restraint to mechanisms of tissue repair has 
been shown in the peripheral nervous system (  48  ). The pres-
ent study also demonstrates this eff  ect on the progression of 
disease in mouse models of AD. Therefore, fi  brin and the 
mechanisms involved in its clearance may present novel ther-
apeutic targets in slowing the progression of AD. 
  MATERIALS AND  METHODS 
  Animals.     The AD transgenic mice used, which develop A    -associated 
pathology, include Tg2576 (  49  ), TgCRND8 (  50  ), and PDAPP (  51  ). 
The Tg2576 mice (APP695; K670N and M671L driven by the human 
prion protein promoter) are on a C57B6/SJL mixed strain background 
and develop cognitive deficits by 9 mo of age. The TgCRND8 mice 
(APP695; K670N, M671L, and V717F driven by the human prion pro-
tein promoter) are on a mixed background (C57XC3H/C57) and ex-
hibit defects in memory as early as 3 mo of age (provided by A. Chishti 
and D. Westaway, University of Toronto, Toronto, Canada). The 
PDAPP mice (APP695, -751, and -770; V717F driven by the platelet-
derived growth factor      promoter) used in this study were backcrossed 
to C57BL/6 mice and display memory defects by 8 mo (provided by 
R.B. Demattos and S.M. Paul, Eli Lilly Research Laboratories, India-
napolis, IN). Mice deficient for plasminogen (  7  ) and fibrinogen (  36, 52  ), 
both backcrossed onto the C57BL/6 background, were used for crosses 
with TgCRND8 and PDAPP mice. Littermates were used in all experi-
ments whenever transgenic mice were compared with nontransgenic 
(wild-type) mice. Where multiple crosses or strains are presented in a 
single figure, nontransgenic littermates from each cross were averaged 
and presented as one bar for clarity and brevity. Mice were maintained in 
the Rockefeller University Laboratory Animal Research Center (LARC) 
and treated in accordance with protocols approved by LARC. 
  Evans blue extravasation assay.     A solution of 2% Evans blue/PBS was 
injected (4 ml/kg) via the tail vein. 6 h after injection, the mice were anesthe-
tized and blood was drawn by cardiac puncture followed by transcardial perfu-
sion with 0.9% saline-heparin (5 U/ml) to remove intravascular dye. One 
brain hemisphere was frozen for sectioning and microscopy studies, whereas 
the other hemisphere was weighed and homogenized in 400     l dimethyl-
formamide to solubilize the Evans blue. To extract the dye, samples were 
centrifuged, and the supernatant was collected and analyzed for absorbance at 
620 nm. The plasma was diluted 1:100 in dimethylformamide and analyzed 
exactly as the brain homogenate. Evans blue units of extravasation were calcu-
lated as the A  620   of brain homogenate divided by the A  620   of plasma. 
  Evans blue fl  uorescence profi  ling.     To visualize the extent of the blood  –
  brain barrier damage, mice were injected via tail vein with Evans blue dye. 
After 6 h, mice were anesthetized and perfused with a solution containing 
large-fragment 2,000-kD FITC-conjugated dextran dissolved in PBS to out-
line the intraluminal space (  53  ). Evans blue fl  uorescence from 50-    m coro-
nal sections was visualized with a laser-scanning confocal imaging system 
(LSM 510 confocal system fi  tted on an Axiovert 200 inverted microscope; JEM VOL. 204, August 6, 2007 
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